Adela Funding & Investors
Foster City, CA
Adela’s mission is to develop innovative and accessible technologies that harness biology and change the way we diagnose and treat disease. Adela’s genome-wide methylation enrichment technology was originally developed by Chief Scientific Officer Dr. Daniel De Carvalho, PhD, at University Health Network’s Princess Margaret Cancer Centre. Adela is initially planning to develop the technology for use across the entire cancer continuum—for detection, diagnosis and management of disease.
adelabio.comTotal Amount Raised: $108,000,000
Adela Funding Rounds
Series A
$48,000,000
Series A Investors
Deerfield ManagementRa Capital ManagementDecheng CapitalOrbiMed AdvisorsLabCorpF-Prime CapitalSeries A
$60,000,000
Series A Investors
F-Prime CapitalDecheng CapitalOrbiMed AdvisorsRa Capital ManagementDeerfield Management
Funding info provided by Diffbot.